Heart failure (HF) is categorized into acute or chronic, and both settings are the focus of this report. While much progress has been made in the pharmacological management of HF, it mainly relates to chronic HF (CHF) with reduced ejection fraction (HFrEF); a significant unmet need remains for CHF with preserved ejection fraction (HFpEF). In addition, the treatment of acute HF (AHF) is dominated by older, generic products. This report provides insights into the continued uptake of Entresto and the potential of several new therapies for CHF (Boehringer Ingelheim/Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Bayer/MSD’s vericiguat, Amgen/Cytokinetics’s omecamtiv mecarbil, and Lexicon Pharmaceuticals’ Zynquista) over the 2018-2028 forecast period. In addition, we assess how the AHF market will evolve given the lack of new drug launches.
- How large is the treatable heart failure population and how will the size of the diagnosed population change over time?
- What is the state of treatment in heart failure? What are the most important drugs and why? What clinical needs remain unfulfilled?
- How will the use of Entresto evolve over the forecast period?
- How will the treatment of HFpEF evolve following the launches of the first evidence-based drugs for this population?
- For which emerging therapies do thought leaders express the most enthusiasm and what level of market penetration can they expect?
United States, France, Germany, Italy, Spain, United Kingdom, Japan
- Heart Failure - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Dominika Rudnicka-Noulin, PhD, MSc; Sunali D. Goonesekera, SM
Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.
Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.
Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.